Uncategorized

Medline hit with FDA warning letter over defective heart syringes, safety hazards

Published

on

After Medline pulled off a massive $6.26 billion IPO late last year, the company now finds itself facing serious concerns being leveled by the FDA.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version